XBiotech announced that it has completed enrollment in its Phase 2, open label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate to severe Atopic Dermatitis, or AD. XBiotech has now completed and exceeded enrollment in the final cohort of patients who are receiving 400mg weekly doses of bermekimab over an 8 week treatment period. Enrollment for the study is now closed. XBiotech recently announced it completed the first cohort of patients in the study who received a low dose of bermekimab over a four week treatment regimen. The company reported that patients in the first cohort had significant improvement in multiple efficacy endpoints and that the treatment was well-tolerated.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.